Interpace Biosciences Inc
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test for the diagnosis of pancreaticobiliary cancers using its proprietary PathFinderTG platform; PanDNA, a molecular only version of PancraGEN; and ThyGeNEXT, an … Read more
Interpace Biosciences Inc - Asset Resilience Ratio
Interpace Biosciences Inc (IDXG) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2017)
This chart shows how Interpace Biosciences Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Interpace Biosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Interpace Biosciences Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Interpace Biosciences Inc Industry Peers by Asset Resilience Ratio
Compare Interpace Biosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF |
Diagnostics & Research | 1.12% |
|
Berry Genomics Co Ltd
SHE:000710 |
Diagnostics & Research | 0.45% |
|
NSN Co. Ltd
KQ:031860 |
Diagnostics & Research | 1.72% |
|
JOONGANG DNM Co.Ltd
KQ:051980 |
Diagnostics & Research | 27.26% |
|
GeneMatrix Inc
KQ:109820 |
Diagnostics & Research | 41.52% |
|
Genoray Co. Ltd
KQ:122310 |
Diagnostics & Research | 0.03% |
|
Green Cross Lab Cell Corporation
KQ:144510 |
Diagnostics & Research | 0.18% |
|
Optipharm.CO.LTD
KQ:153710 |
Diagnostics & Research | 20.73% |
Annual Asset Resilience Ratio for Interpace Biosciences Inc (2000–2017)
The table below shows the annual Asset Resilience Ratio data for Interpace Biosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $53.60 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $41.78 Million | -- |
| 2015-12-31 | 0.16% | $106.00K | $67.71 Million | +0.06pp |
| 2014-12-31 | 0.09% | $107.00K | $115.91 Million | -0.06pp |
| 2013-12-31 | 0.15% | $103.00K | $69.06 Million | +0.03pp |
| 2012-12-31 | 0.12% | $92.00K | $78.45 Million | +0.01pp |
| 2011-12-31 | 0.11% | $127.00K | $113.38 Million | -0.07pp |
| 2010-12-31 | 0.18% | $227.00K | $124.39 Million | -3.30pp |
| 2009-12-31 | 3.48% | $3.82 Million | $109.78 Million | +3.37pp |
| 2008-12-31 | 0.11% | $159.00K | $149.04 Million | -4.24pp |
| 2007-12-31 | 4.34% | $7.80 Million | $179.55 Million | -30.11pp |
| 2006-12-31 | 34.45% | $69.46 Million | $201.64 Million | +31.05pp |
| 2005-12-31 | 3.40% | $6.81 Million | $200.31 Million | -2.45pp |
| 2004-12-31 | 5.84% | $13.13 Million | $224.71 Million | +5.23pp |
| 2003-12-31 | 0.61% | $1.34 Million | $219.62 Million | -2.44pp |
| 2002-12-31 | 3.06% | $5.83 Million | $190.94 Million | +0.61pp |
| 2001-12-31 | 2.44% | $7.39 Million | $302.67 Million | +0.62pp |
| 2000-12-31 | 1.82% | $4.91 Million | $270.23 Million | -- |